ATOS
Price
$0.86
Change
+$0.02 (+2.38%)
Updated
May 2, 04:59 PM (EDT)
Capitalization
110.49M
17 days until earnings call
OCGN
Price
$0.77
Change
+$0.02 (+2.70%)
Updated
May 2, 04:59 PM (EDT)
Capitalization
223.39M
Earnings call today
Ad is loading...

ATOS vs OCGN

Header iconATOS vs OCGN Comparison
Open Charts ATOS vs OCGNBanner chart's image
Atossa Therapeutics
Price$0.86
Change+$0.02 (+2.38%)
Volume$2.03K
Capitalization110.49M
Ocugen
Price$0.77
Change+$0.02 (+2.70%)
Volume$16.33K
Capitalization223.39M
ATOS vs OCGN Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. OCGN commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and OCGN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (ATOS: $0.84 vs. OCGN: $0.74)
Brand notoriety: ATOS and OCGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 145% vs. OCGN: 69%
Market capitalization -- ATOS: $110.49M vs. OCGN: $223.39M
ATOS [@Biotechnology] is valued at $110.49M. OCGN’s [@Biotechnology] market capitalization is $223.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.17B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileOCGN’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • OCGN’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than OCGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 5 TA indicator(s) are bullish while OCGN’s TA Score has 5 bullish TA indicator(s).

  • ATOS’s TA Score: 5 bullish, 5 bearish.
  • OCGN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OCGN is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а +15.07% price change this week, while OCGN (@Biotechnology) price change was +0.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.36%. For the same industry, the average monthly price growth was +8.08%, and the average quarterly price growth was -5.89%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

OCGN is expected to report earnings on Aug 01, 2025.

Industries' Descriptions

@Biotechnology (+4.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCGN($223M) has a higher market cap than ATOS($110M). OCGN YTD gains are higher at: -8.311 vs. ATOS (-10.709). ATOS has higher annual earnings (EBITDA): -29.46M vs. OCGN (-52.79M). ATOS has more cash in the bank: 74.8M vs. OCGN (58.5M). ATOS has less debt than OCGN: ATOS (0) vs OCGN (32.5M). OCGN has higher revenues than ATOS: OCGN (4.06M) vs ATOS (0).
ATOSOCGNATOS / OCGN
Capitalization110M223M49%
EBITDA-29.46M-52.79M56%
Gain YTD-10.709-8.311129%
P/E RatioN/AN/A-
Revenue04.06M-
Total Cash74.8M58.5M128%
Total Debt032.5M-
FUNDAMENTALS RATINGS
ATOS vs OCGN: Fundamental Ratings
ATOS
OCGN
OUTLOOK RATING
1..100
1019
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9396
PRICE GROWTH RATING
1..100
4860
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (30) in the Medical Specialties industry is somewhat better than the same rating for OCGN (65) in the null industry. This means that ATOS’s stock grew somewhat faster than OCGN’s over the last 12 months.

OCGN's Profit vs Risk Rating (94) in the null industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that OCGN’s stock grew similarly to ATOS’s over the last 12 months.

ATOS's SMR Rating (93) in the Medical Specialties industry is in the same range as OCGN (96) in the null industry. This means that ATOS’s stock grew similarly to OCGN’s over the last 12 months.

ATOS's Price Growth Rating (48) in the Medical Specialties industry is in the same range as OCGN (60) in the null industry. This means that ATOS’s stock grew similarly to OCGN’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as OCGN (100) in the null industry. This means that ATOS’s stock grew similarly to OCGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSOCGN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
89%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RPFRX40.400.16
+0.40%
Davis Real Estate A
IBALX32.95N/A
N/A
Transamerica Multi-Managed Balanced A
FICHX12.33N/A
N/A
Cantor Fitzgerald Large Cap Fcs Cl Inst
JHDCX17.83N/A
N/A
JPMorgan Hedged Equity 2 C
ELMFX16.31N/A
N/A
Lord Abbett Emerging Markets Equity F